Survival benefit in EGFR-wild and ALK negative NSCLC patients who participate in clinical trials compared to standard-of-care: Propensity-matched analysis
Over the past two decades, remarkable progress has been made in therapeutic applications for non-small-cell lung cancer (NSCLC), with fundamental knowledge of tumor biology and drug development. Notably, spectacular advances in the management of NSCLC have been accomplished in clinical trials.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Hyun-Ae Jung, Boram Park, Sehhoon Park, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn Tags: Research Paper Source Type: research
More News: Biology | Cancer | Cancer & Oncology | Clinical Trials | Lung Cancer | Non-Small Cell Lung Cancer